ID   OACM5.1 C
AC   CVCL_1842
SY   OAC-M5.1 C; OAC-M5.1; OACM5-1; OACM5.1; OACM5_1; OACM51
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 970
DR   BioSample; SAMN03473445
DR   cancercelllines; CVCL_1842
DR   Cell_Model_Passport; SIDM00444
DR   Cosmic; 1599344
DR   Cosmic-CLP; 1503363
DR   DepMap; ACH-001368
DR   DSMZ; ACC-696
DR   DSMZCellDive; ACC-696
DR   ECACC; 11012006
DR   EGA; EGAS00001000978
DR   GDSC; 1503363
DR   GEO; GSM1670290
DR   PharmacoDB; OACM51_1176_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54931676
RX   PubMed=11407472;
RX   PubMed=20075370;
RX   PubMed=23795680;
RX   PubMed=27397505;
RX   PubMed=27594985;
RX   PubMed=28504813;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~48 hours (DSMZ=ACC-696).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.02%; East Asian, North=0%; East Asian, South=0%; South Asian=1.6%; European, North=72.08%; European, South=26.29% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=20075370
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 11,12
ST   D16S539: 10,11
ST   D18S51: 16
ST   D19S433: 14,15
ST   D21S11: 28,31
ST   D2S1338: 19,24
ST   D3S1358: 16,17
ST   D5S818: 11,12 (Cosmic-CLP; DSMZ; ECACC)
ST   D5S818: 12 (PubMed=20075370)
ST   D7S820: 8 (Cosmic-CLP; DSMZ; PubMed=20075370)
ST   D7S820: 8.2 (ECACC)
ST   D8S1179: 13 (DSMZ)
ST   D8S1179: 13,14 (PubMed=20075370)
ST   FGA: 22
ST   Penta D: 10
ST   Penta E: 7,14
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 19,20
DI   NCIt; C4025; Esophageal adenocarcinoma
DI   ORDO; Orphanet_99976; Adenocarcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 30
//
RX   PubMed=11407472; DOI=10.1007/s004280000358;
RA   de Both N.J., Wijnhoven B.P.L., Sleddens H.F.B.M., Tilanus H.W.,
RA   Dinjens W.N.M.;
RT   "Establishment of cell lines from adenocarcinomas of the esophagus and
RT   gastric cardia growing in vivo and in vitro.";
RL   Virchows Arch. 438:451-456(2001).
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27594985; DOI=10.12688/f1000research.7033.1;
RA   Contino G., Eldridge M.D., Secrier M., Bower L., Elliott R.F., Weaver J.,
RA   Lynch A.G., Edwards P.A.W., Fitzgerald R.C.;
RT   "Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.";
RL   F1000Research 5:1336.1-1336.12(2016).
//
RX   PubMed=28504813; DOI=10.3892/or.2017.5640;
RA   Melsens E., De Vlieghere E., Descamps B., Vanhove C., De Wever O.,
RA   Ceelen W., Pattyn P.;
RT   "Improved xenograft efficiency of esophageal adenocarcinoma cell lines
RT   through in vivo selection.";
RL   Oncol. Rep. 38:71-81(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//